Keros Therapeutics Presented Additional Data From Its Two Ongoing Phase 2 Trials Of Elritercept (KER-050), For Very Low-, Low-, Or Intermediate-Risk Myelodysplastic Syndromes And Myelofibrosis
Keros Therapeutics Presented Additional Data From Its Two Ongoing Phase 2 Trials Of Elritercept (KER-050), For Very Low-, Low-, Or Intermediate-Risk Myelodysplastic Syndromes And Myelofibrosis
keros therapeutics給出了Elritercept（KER-050）用於非常低危、低危或中度危險的骨髓增生異常綜合症和骨髓纖維化的兩項進行中的2期試驗的補充數據。
- Elritercept continued to demonstrate a durable transfusion independence in lower-risk myelodysplastic syndromes, including in patients with high transfusion burden.
- Durable clinical responses were associated with improvements in patient-reported measures of fatigue.
- Data from ongoing Phase 2 clinical trial in myelofibrosis continue to demonstrate that elritercept can not only ameliorate ineffective hematopoiesis and address cytopenias, but also provide broader clinical benefit, as supported by observed reductions in spleen volume and improved total symptom scores.
- 在低風險骨髓增生異常綜合症中，Elritercept持續展現出耐用的輸注獨立性，包括高輸注負擔的患者。
- 耐用的臨床反應與疲勞的患者報告指標的改善相關。
- 來自骨髓纖維化正在進行的II期臨床試驗的數據始終表明，Elritercept不僅可以改善無效造血和處理細胞減少症，還能提供更廣泛的臨床益處，如觀察到的脾臟體積減小和改善的總症狀評分所支持。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。